Jammu: Union Minister Jitendra Singh on Saturday laid the foundation stone of a Rs 600 crore pharmaceutical manufacturing facility in Kathua district, in a bid to strengthen India's strategic capabilities in pharmaceutical manufacturing and reduce import dependence on critical intermediates.

查谟：联邦部长吉滕德拉·辛格周六在卡图阿区奠基了一座耗资6亿卢比的制药生产设施，旨在加强印度在制药制造领域的战略能力，并减少对关键中间体的进口依赖。

The facility will manufacture the critical antibiotic intermediate

该设施将生产关键的抗生素中间体

Amino Cephalosporanic Acid

氨基头孢菌酸

(ACA), a key component in the production of cephalosporin antibiotics.

(ACA)，是生产头孢菌素抗生素的关键成分。

The project at village Gadadhar is being set up by

该项目正在加达达尔村设立，

Orchid Pharma

兰花制药

with facilitation from Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology, an official said.

在生物技术产业研究援助委员会（BIRAC）的促进下，该委员会隶属于生物技术部，一位官员表示。

Also Read:

另请阅读：

India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25

印度原料药出口额达4150亿卢比，超过2025财年的进口额。

'The investment of around Rs 600 crore, being made under the government's Production-Linked Incentive Scheme, reflects growing confidence in the industrial and innovation potential of Jammu and Kashmir,' the Union Minister said.

“在政府的生产挂钩激励计划下，约6亿卢比的投资反映了对查谟和克什米尔工业和创新潜力的信心日益增强，”联邦部长表示。

Live Events

现场活动

He said the facility is expected to generate direct employment for nearly 400 people, while creating an equal number of indirect employment opportunities for suppliers, logistics providers and other allied sectors.

他说，该工厂预计将为近400人提供直接就业机会，同时为供应商、物流供应商和其他相关行业创造数量相当的间接就业机会。

Singh highlighted that with its growing industrial infrastructure, Kathua has the potential to emerge as a significant pharmaceutical manufacturing hub.

辛格强调，随着其工业基础设施的不断增长，卡图阿有潜力成为重要的制药业制造中心。

The minister described the project as a breakthrough for the pharmaceutical sector in the region, noting that the facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA).

部长形容该项目为该地区制药业的突破，并指出该设施将生产关键的抗生素中间体氨基头孢烷酸（ACA）。

Also Read:

另请阅读：

'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

“印度拥有成为生物医学创新领导者的智力优势，”拜耳公司表示。

At present, India depends almost entirely on imports of this intermediate from China, which creates vulnerabilities in supply security, pricing stability and healthcare access.

目前，印度几乎完全依赖从中国进口这种中间体，这在供应安全、价格稳定和医疗保健获取方面造成了漏洞。

'Antibiotics are foundational to modern healthcare, and the pandemic showed how dependence on a single geography for essential inputs can quickly become a national vulnerability,' he said.

“抗生素是现代医疗的基石，而疫情表明，对单一地理区域提供基本投入的依赖如何迅速成为国家的脆弱性，”他说。

Highlighting the broader policy vision, Singh said the initiative reflects the vision of Prime Minister Narendra Modi to make India self-reliant in critical healthcare technologies and pharmaceutical supply chains.

辛格强调了更广泛的政策愿景，他表示，该倡议反映了总理纳伦德拉·莫迪使印度在关键医疗技术和制药供应链上实现自力更生的愿景。

He also referred to the newly announced Rs 10,000 crore Biopharma Shakti initiative in the Union Budget aimed at strengthening India's biotechnology and biopharmaceutical ecosystem.

他还提到了联邦预算中最新宣布的1000亿卢比的“生物制药力量”倡议，该倡议旨在加强印度的生物技术和生物制药生态系统。

'The establishment of such advanced pharmaceutical manufacturing units has the potential to place Kathua on India's pharmaceutical export map,' he said.

他说：“建立如此先进的制药生产单位有可能使卡图阿进入印度的制药出口版图。”

The Minister said projects like this not only expand India's pharmaceutical capacity but also strengthen the country's health security by ensuring the availability and affordability of essential medicines even during global disruptions.

部长表示，像这样的项目不仅扩大了印度的制药能力，还通过确保在发生全球动荡期间基本药物的可得性和可负担性来增强该国的卫生安全。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)